PlainRecalls
FDA Devices Critical Class I Terminated

Lyra SARS-CoV-2 Assay (M120) in vitro diagnostic test reagent

Reported: July 7, 2021 Initiated: April 27, 2021 #Z-1928-2021

Product Description

Lyra SARS-CoV-2 Assay (M120) in vitro diagnostic test reagent

Reason for Recall

In rare situations patients infected with high viral load of SARS CoV 2 may have samples that generate Ct values less than or equal to (d) 5 when certain amplification and detection platforms (thermocyclers) are used. These specimens would be falsely interpreted as negative if target amplification occurs prior to a cycle threshold (Ct) value of 5. There have been no formal complaints of False Negative results with Ct values <5 from Lyra SARS-CoV-2 Assay users.

Details

Recalling Firm
Quidel Corporation
Units Affected
29,787 kits (96 results/kit)
Distribution
Worldwide distribution - US Nationwide distribution in the states of AL, CA, CT, DC, FL, ID, IN, MA, MI, MO, NM, NY, OH, SC, TN, TX, WA and the countries of Canada, Saudi Arabia, United Kingdom.
Location
Athens, OH

Frequently Asked Questions

What product was recalled?
Lyra SARS-CoV-2 Assay (M120) in vitro diagnostic test reagent. Recalled by Quidel Corporation. Units affected: 29,787 kits (96 results/kit).
Why was this product recalled?
In rare situations patients infected with high viral load of SARS CoV 2 may have samples that generate Ct values less than or equal to (d) 5 when certain amplification and detection platforms (thermocyclers) are used. These specimens would be falsely interpreted as negative if target amplification occurs prior to a cycle threshold (Ct) value of 5. There have been no formal complaints of False Negative results with Ct values <5 from Lyra SARS-CoV-2 Assay users.
Which agency issued this recall?
This recall was issued by the FDA Devices on July 7, 2021. Severity: Critical. Recall number: Z-1928-2021.